| Features: |
Fewer user steps
Pre-coated 96 well capture antibody plates
High signal to noise ratio
Detection sensitivity of 2 pg/ml of PAR
Broad linear dynamic range to 1,000 pg/ml
Reduced inter-assay variability
Commercially available validated assay that measures drug action on PARP in both in vivo and in vitro settings
|
| |
| Applications: |
Quantification of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts.
Monitoring the efficacy of PARP inhibitors on PAR formation in vivo.
Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.
Facilitating development of PARP and PARG targeted therapeutics
|
| |
| Components: |
Part # |
Component |
Size |
| |
4520-096-01 |
PAR Standard, 25 pg/μl |
5 x 20 μl |
| |
4520-096-02 |
Sample Buffer |
20 ml |
| |
4520-096-03 |
PAR Polyclonal Detecting Antibody |
30 μl |
| |
4520-096-04 |
Goat anti-Rabbit IgG-HRP |
30 μl |
| |
4675-096-01 |
PARP PeroxyGlow™ A |
6 ml |
| |
4675-096-02 |
PARP PeroxyGlow™ B |
6 ml |
| |
4520-096-05 |
Cell Lysis Reagent |
30 ml |
| |
4520-096-06 |
DNase 1, 2 Units/μl |
60 μl |
| |
4520-096-07 |
100X Magnesium Cation |
500 μl |
| |
4520-096-P |
Pre-coated white 96-stripwell plate, and 5 sealers |
1 plate |
| |
4520-096-08 |
Jurkat Cell Lysate Standard Control, Low |
600 μl |
| |
4520-096-09 |
Jurkat Cell Lysate Standard Control, Medium |
600 μl |
| |
4520-096-10 |
Jurkat Cell Lysate Standard Control, High |
600 μl |
| |
4520-096-11 |
Antibody Diluent |
15 ml |
| |
4520-096-12 |
20% (w/v) SDS |
1 ml |
| |
| Storage: |
Components are stored at -80°C, -20°C, 4°C, and room temperature |
| |
| References: |
1. Virag, L., and Szabo, C. 2002. The therapeutic potential of Poly(ADP-Ribose) Polymerase inhibitors. Pharmacological Reviews 54:375-429.
2. Thiemermann, C., J. Bowes, F.P. Myint, and J.R. Vane. 1997. Inhibition of the activity of poly(ADP-ribose) synthase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94:679-83.
3. Curtin NJ. 2005. PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1-20.
4. Kinders JK, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE, and the National Cancer Institute Phase 0 Clinical Trials Team. 2008. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res 14:6877-85.
|
